We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Pregnancy outcomes in women receiving eculizumab for the management of paroxysmal nocturnal haemoglobinuria.
- Authors
Manning, James E; Anderson, Rachel M; Hill, Anita; Zeidan, Doaa; Ciantar, Etienne
- Abstract
Aims: To report pregnancy outcomes and complications in women receiving eculizumab for the management of paroxysmal nocturnal haemoglobinuria. Methods: A service evaluation of routinely collected medical records across 49 pregnancies in 21 women. Results: Eculizumab was used in 37 pregnancies, 31 of which (83.8%) ended in live birth. Eight infants (25.8%) were born prematurely. Over half (54%) of women required increases in their dose of eculizumab to control their haemolysis. There were no reported cases of maternal thrombosis. Major ante/postpartum bleeding necessitating urgent intervention was reported in 10.8% of pregnancies. There were two cases of intrauterine death and three miscarriages. There were no maternal or neonatal deaths. Three newborns required prolonged hospital stays. Conclusions: Eculizumab appears to benefit pregnant women with paroxysmal nocturnal haemoglobinuria and pregnancy outcomes following its use are largely good.
- Subjects
HEMOLYTIC anemia; POSTPARTUM hemorrhage; PREMATURE infants; HEMOLYSIS &; hemolysins; MISCARRIAGE; MONOCLONAL antibodies; PREGNANT women; PREGNANCY outcomes; PERINATAL death; PREGNANCY complications; MEDICAL records; PREGNANCY
- Publication
Obstetric Medicine (1753-495X), 2022, Vol 15, Issue 1, p45
- ISSN
1753-495X
- Publication type
Article
- DOI
10.1177/1753495X211019899